LBA10 A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)

L Zhang ,X Hu,Z Zhou,H Zhang ,B Lan ,J Zhang ,J Chen ,L Chen ,D Wu ,J Zhu ,Q Yu ,G Wu ,Shaowei Pan ,Tieqiang Kong ,Huishu Lin ,Y Lin ,Wenxin Fang ,Xin-Yuan Lei ,Z Wang ,H Yu

doi:10.1016/j.annonc.2022.10.352

LBA10 A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)

L Zhang , X Hu + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.352

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Sun Yat-sen University Cancer Center, Sun Yat-sen University

#EGFR Mutation-positive Advanced Non-small Cell #Mutation-positive Advanced Non-small Cell Lung + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Anlotinib（Catequentinib） is an oral multi-targeted tyrosine kinase inhibitor that effectively inhibits VEGFRs, FGFRs, PGFRs, c-kit and MET. This phase III study aims to evaluate the efficacy and safety of Anlotinib or placebo plus Gefitinib in patients (pts) with untreated EGFR-mutated metastatic NSCLC.

Full Text